Deduction of a facile method to construct Antheraea mylitta silk fibroin/gelatin blend films for prospective biomedical applications

Blend films of two types (I and II) were prepared by mixing Antheraea mylitta silk fibroin (AMF) and gelatin solution in various blend ratios via the solution casting method. Two different crosslinkers, namely glutaraldehyde and genipin, were used during blend preparation. The structural characteristics and thermal properties of the blend films were examined by Fourier transform infrared (FTIR) spectroscopy, X‐ray diffraction (XRD), Thermogravimetric analysis (TGA) and Diffrential scanning calorimetery (DSC). The FTIR spectra showed conformational alterations in type I blend films while type II films attained high β‐sheet crystallinity. The XRD diffractograms presented a high degree of crystallinity in type II blend films compared to type I, which showed an almost amorphous structure. Further, thermal and biological studies were conducted on type II films. According to the TGA thermograms, the degradation temperature of the crosslinked blend films shifted compared to pure gelatin and pure AMF films. Partial miscibility of the two components was indicated by DSC thermograms of the blends. The high water uptake capacity of type II blend films was found to imitate hydrogel behaviour. The blend films did not show any toxicity in 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide (MTT) assay and supported L929 fibroblast cell spreading and proliferation. The biodegradation of the blend films was significantly faster than the pure silk film. © 2020 Society of Industrial Chemistry     

Retinal vessel dilatation and elongation precedes diabetic macular oedema

Rolandic discharge (RD), noted in the electroencephalography (EEG) of patients with benign epilepsy in childhood with centrotemporal spikes (BECCT) has several unique features. One feature is that the amount or frequency of RDs does not correlate well with the incidence of seizures in BECCT although it is a key finding in the diagnosis of this epileptic syndrome. In this study, we examined the efficacy of antiepileptic drugs focusing on the disappearance of RDs in relationship with seizure control. Forty patients with BECCT who were not medically treated prior to this study were randomly sorted into three groups. Twenty patients were assigned for clonazepam (CZP) treatment, 10 patients for valproate (VPA) and the remaining 10 patients for carbamazepine (CBZ). Each drug was administered for 4 consecutive weeks. EEGs were recorded twice during the study, before and 4 weeks after the medication trial. The effects of each treatment on RDs were assessed. RDs disappeared in 15 of the 20 cases treated with CZP (75%) within 4 weeks while the same was observed in only one of the 10 cases treated with VPA (10%). CBZ failed to demonstrate any effect on RD. In the group treated with CZP, there were no differences in seizure incidence, seizure type and blood concentration of CZP between the patients whose RDs disappeared and those whose RDs remained.     

Facial myokymia and spastic paretic facial contracture as the result of anaplastic pontocerebellar glioma

The case of a 36-year-old man who sought treatment of right facial myokymia and spastic paretic facial contracture is reported. Computed tomography and magnetic resonance imaging revealed a tumor located in the right cerebellar peduncle and the right dorsal pons bulging into the fourth ventricle. After microsurgical partial resection of the mass, which was verified histologically as an anaplastic glioma, facial myokymia initially ceased. The vermicular rippling movements were less intense upon recurrence and could be controlled by low-dose dexamethasone in the further course, when magnetic resonance imaging showed an interstitial pontine edema after percutaneous radiation therapy. It is assumed that facial myokymia and spastic paretic facial contracture were generated by ectopic activity due to alterations in the microenvironment at the intrapontine portion of the axons of the seventh nerve caused by the compressive effect of the tumor and later by edema.     

Interface cracking between functionally graded coatings and a substrate under antiplane shear

Coating technology plays a significant role in a number of applications such as high temperatures, corrosion, oxidation, wear, and interface. In this paper, we investigate the interface cracking between ceramic and/or functionally graded coatings (FGM coatings) and a substrate under antiplane shear. Four coating models are considered, namely single layered homogeneous coating, double layered piece-wise homogeneous coating, single layered FGM coating and double layered coating with an FGM bottom coat. Mode III stress intensity factors (SIFs) are calculated for the different coating models. In the case of μ_L > μ₀ where μ₀ is the shear modulus of the substrate and μ_L the shear modulus of the material at the surface of the coating, it is found that the single layered FGM coating reduces SIF slightly, whereas the coating system with a top homogeneous layer and a thin FGM bottom layer reduces SIF significantly. In the case of μ_L < μ₀ the SIF is found to be larger for the FGM coatings than for the homogeneous coatings. The FGM coating, however, may still be superior to homogeneous coatings in this case as FGM coatings usually provide better bonding strength between the coating and substrate. Finally, the applicability of the SIF concept in the fracture of FGM coatings is discussed. Large modulus gradients in thin coatings may seriously restrict the application of SIFs as the SIF-dominant zone may fall into the crack tip nonlinear deformation and damage zone. The same argument exists for some interphase models in interface crack solutions.     

Development of a monoclonal antibody to 6 beta-hydroxycortisol and its application in an enzyme-linked immunosorbent assay (ELISA) for 6 beta-hydroxycortisol in urine

A novel monoclonal antibody to 6 beta-hydroxycortisol (6 beta-OHC) was generated and incorporated into an antigen-coated indirect enzyme-linked immunosorbent assay (ELISA) using 6 beta-OHC-protein conjugate as the steroid-coating antigen. The monoclonal antibody is specific to 6 beta-OHC and 6 beta-OHC-3-carboxymethyloxime. Cross-reactivity with other structurally related steroids such as cortisol, cortisone, and 6 beta-hydroxycortisone was less than 10%. Two different clones (clone 5C1 and 19F) of the monoclonal anti-6 beta-OHC antibody have been developed, each with slightly different sensitivity and specificity. The sensitivity of the MAb clones was not significantly improved when compared to the rabbit polyclonal antibodies in this study, but still within the accepted detection limit for 6 beta-OHC in both human and laboratory animals. The assay had a detection limit of 200 ng/ml, an intraassay variation of 6.4% and an interassay variation of 7.3%. The application of the anti-6 beta-OHC-MAb-based-ELISA was tested by measuring the urinary output of 6 beta-OHC in human before and after enzyme induction by rifampicin treatment. The mean 24-h urine output of 6 beta-OHC in human subjects was 485 +/- 100 micrograms and 1478 +/- 281 micrograms before and after rifampicin administration, respectively. In conclusion, the monoclonal anti-6 beta-OHC antibody developed in this study has the required specificity and sensitivity as an alternative method for measuring urinary 6 beta-OHC in the detection of enzyme induction or enzyme inhibition of CYP3A in humans and laboratory animals.     

CEO summit. Building the new health care delivery alliance, Part III. Roundtable discussion

In cooperation with McManis Associates, Hospitals & Health Networks recently convened a CEO summit on physician/hospital integration activities. In the third report of a three-part series on the summit, leading health care executives discuss investor capital needs, strategic information management needs, and the management competencies required for capitated managed care success.     

Association of INAD with NORPA is essential for controlled activation and deactivation of Drosophila phototransduction in vivo

Visual transduction in Drosophila is a G protein-coupled phospholipase C-mediated process that leads to depolarization via activation of the transient receptor potential (TRP) calcium channel. Inactivation-no-afterpotential D (INAD) is an adaptor protein containing PDZ domains known to interact with TRP. Immunoprecipitation studies indicate that INAD also binds to eye-specific protein kinase C and the phospholipase C, no-receptor-potential A (NORPA). By overlay assay and site-directed mutagenesis we have defined the essential elements of the NORPA-INAD association and identified three critical residues in the C-terminal tail of NORPA that are required for the interaction. These residues, Phe-Cys-Ala, constitute a novel binding motif distinct from the sequences recognized by the PDZ domain in INAD. To evaluate the functional significance of the INAD-NORPA association in vivo, we generated transgenic flies expressing a modified NORPA, NORPAC1094S, that lacks the INAD interaction. The transgenic animals display a unique electroretinogram phenotype characterized by slow activation and prolonged deactivation. Double mutant analysis suggests a possible inaccessibility of eye-specific protein kinase C to NORPAC1094S, undermining the observed defective deactivation, and that delayed activation may similarly result from NORPAC1094S being unable to localize in close proximity to the TRP channel. We conclude that INAD acts as a scaffold protein that facilitates NORPA-TRP interactions required for gating of the TRP channel in photoreceptor cells.     

Haemangiopericytoma of the nasal cavity

Haemangiopericytoma of nose and paranasal sinuses is relatively uncommon tumour. It occurs in adults in sixth and seventh decades of life. In view of paucity of intranasal haemangiopericytoma old in Indian literature and young age of patient, we are reporting one case in 28-year-old female who presented with recurrent, profuse epistaxis.